[徵paper]兩篇
Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
Formica V, Massara MC, Portarena I, Fiaschetti V, Grenga I, Del Vecchio Blanco G, Sileri P, Tosetto L, Skoulidis F, Pallone F, Roselli M.
Cancer Biomark. 2009;5(4):167-75.
Carcinoembryonic antigen in monitoring of response to cetuximab plus FOLFIRI or FOLFOX-4 in patients with metastatic colorectal cancer.
Tsai HL, Chang YT, Chu KS, Chen CF, Yeh YS, Ma CJ, Wu DC, Kuo CH, Chan HM, Sheen MC, Wang JY.
Int J Biol Markers. 2008 Oct-Dec;23(4):244-8.
我的信箱是hjj7tony@yahoo.com.tw
感謝您
--
※ 發信站: 批踢踢實業坊(ptt.cc)
◆ From: 42.76.126.225
推
09/12 10:45, , 1F
09/12 10:45, 1F
→
09/12 16:07, , 2F
09/12 16:07, 2F
討論串 (同標題文章)
medstudent 近期熱門文章
PTT職涯區 即時熱門文章